Sarah Kathryn Rouan, Director at Viking Therapeutics, Inc. (VKTX), sold 11,000 shares at $80.89 ($890K) on 2024-10-25, disclosed to the SEC on 2024-10-25.
Scheduled sale ($890k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VKTX | SELL | 2024-01-19 | $692K | — | Filing → |
| NAVB | BUY | 2019-05-21 | $5K | — | Filing → |